Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.36 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8619802 | 0.69 | SIRT2 (0.34) | — | |
| SCHEMBL10150407 | 0.64 | PARP1 (0.59) | PARP1CYP1A2HIF1APARP15PARP3 | |
| SCHEMBL3122203 | 0.64 | PARP1 (0.59) | PARP1CYP1A2HIF1APARP15PARP3 | |
| SCHEMBL5257298 | 0.63 | GRIN1 (0.37) | — | |
| SCHEMBL10581919 | 0.63 | SIRT2 (0.37) | — | |
| SCHEMBL25687536 | 0.63 | SIRT2 (0.31) | — | |
| SCHEMBL7782060 | 0.63 | CYP1A2 (0.42) | PARP1CYP1A2HIF1APARP15PARP3 | |
| SCHEMBL4433128 | 0.61 | GRIN2D (0.38) | — | |
| SCHEMBL30850338 | 0.61 | PARP1 (0.36) | PARP1CYP1A2HIF1APARP15PARP3 | |
| SCHEMBL8852255 | 0.60 | ESR1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656354-B1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| EP-1656354-B1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-7223767-B2 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223767-B2 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223767-B2 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1656354-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050038052-A1 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | ROCHE PALO ALTO LLC | 2005-02-17 | — | — | US | disclosed |
| WO-2005014557-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038052-A1 | Tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | CRHR1, AVPR2, CRHR2 | PARP1 3416/4885CYP1A2 497/4885HIF1A 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.